OBJECTIVE： To investigate clinical efficacy and safety of conjugeted estrogen tablets combined with Salmon calcitonin acetate injection and Alendronate sodium tablets in the treatment of osteoporosis in postmenopausal. METHODS： 148 postmenopausal women with osteoporosis were randomly divided into observation group （78 cases） and control group （70 cases）. Control group was given Salmon calcitonin acetate injection hypodermically or intramuscularly， 100 IU each time， once a day in first week， every two days in second week， every three days in third week， 21 times of consecutive injection as a treatment course； Alendronate sodium tablet， 70 mg each time， once a week， 3 months as a treatment course. Based on control group， observation group was additionally given conjugeted estrogen tablets， 0.625 mg each time， qd， for consecutive 3 weeks， drug withdrawal for one week， and then continued to taking drug， for 3 months in total. Clinical efficacy of 2 groups were observed as well as BGP， bone metabolism index as human collagen type Ⅰ N-terminal peptide （NTX） and ALP， bone density and ADR before and after treatment. RESULTS： After treatment， total effective rate of observation group was 94.87％， which was significantly higher than 78.57％ in control group， with statistical significance （P＜0.05）； BGP， lumbar spine and thigh-bone density of 2 groups were all improved significantly， and the improvement of observation group was more significant than that of control group， with statistical significance （P＜0.05）. NTX and ALP of 2 groups were decreased significantly， and the decrease of observation group was more significant than that of control group， with statistical significance （P＜0.05）. The incidence of ADR was 12.82％ in observation group and 8.57％ in control group， without statistical significance （P＞0.05）； various ADR disappeared after drug withdrawal. CONCLUSIONS： Conjugeted estrogen tablets combined with Salmon calcitonin acetate injection and Alendronate sodium tablets can effectively relieve bone pain， regulate bone metabolism， increase bone density and induce slight ADR in postmenopausal with osteoporosis.